Viridium Pacific Group Ltd.: Experion Completes First Sale

Viridium Pacific Group Ltd.: Experion Completes First Sale

October 1, 2018 — Viridium Pacific Group Ltd. (“Viridium” or the “Company”) (TSXV: VIR) (OTCPink: VIRFF) is pleased to announce its wholly owned subsidiary, Experion Biotechnologies Inc. (“Experion”), has completed its first sale of dried medical cannabis to one of the largest Licensed Producer (“LP”) in Canada headquartered British Columbia. The buyer of Experion’s first commercially available product is one of Canada’s industry leaders in medical cannabis cultivation and research with one of the longest track records of excellence and quality. The sale follows Experion receiving its medical wholesale license from Health Canada on August 18, 2018, and officially launches its wholesale business. This first sale validates Experion’s product has met or exceeded the product quality, sanitation and handling, production practice, and quality control standards of a leading medical cannabis distributor. Subsequent sales are being considered including supplier agreements to other LP’s and provincial distributors and we will keep the market informed as these become finalized.

Mr. Jarrett Malnarich, Viridium CEO, commented, “We are very excited launching our wholesale business and looking forward to future sales in both the medical and non-medical recreational markets. We have been ultra focused on procuring and cultivating quality strains ahead of our first sales transaction, and we are very pleased to have met the high standards of one of Canada’s leaders in the space.”

About Viridium

Viridium Pacific Group Ltd. is the parent company of operating subsidiaries involved in horticultural production, (Experion Biotechologies Inc.) property development (Fish Trap Ventures Ltd.), and human resource management (Stave Lake Services Ltd.) Experion Biotechnologies Inc., is a Health Canada licensed producer of cannabis, which operates in an 8,300 square-foot indoor facility outside of Mission, BC.

More information about Viridium can be found under the Company’s profile on SEDAR at www.sedar.com.

Disclosure

This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.

Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s equity securities; recent market volatility; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.